Adaptimmune Therapeutics

NASDAQ: ADAP · Real-Time Price · USD
0.28
0.00 (1.78%)
At close: May 02, 2025, 3:59 PM
0.29
1.44%
After-hours: May 02, 2025, 05:26 PM EDT
1.78%
Bid 0.26
Market Cap 72.84M
Revenue (ttm) 178.03M
Net Income (ttm) -70.81M
EPS (ttm) -0.3
PE Ratio (ttm) -0.95
Forward PE -0.77
Analyst Buy
Ask 0.3
Volume 453,273
Avg. Volume (20D) 1,678,464
Open 0.27
Previous Close 0.28
Day's Range 0.28 - 0.29
52-Week Range 0.20 - 1.48
Beta 2.84

About ADAP

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposa...

Industry Biotechnology
Sector Healthcare
IPO Date May 6, 2015
Employees 506
Stock Exchange NASDAQ
Ticker Symbol ADAP
Full Company Profile

Analyst Forecast

According to 5 analyst ratings, the average rating for ADAP stock is "Buy." The 12-month stock price forecast is $1.5, which is an increase of 427.06% from the latest price.

Stock Forecasts

Next Earnings Release

Adaptimmune Therapeutics is scheduled to release its earnings on May 14, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
-37.65%
Adaptimmune Therapeutics shares are trading lower ... Unlock content with Pro Subscription
5 months ago
-23.28%
Adaptimmune Therapeutics shares are trading lower. The company reported Q3 financial results.